Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Tuesday, April 25, 2017
 
Recommended for you
Gilead Sciences: A Future Dividend Gold Mine At A Bargain Price
Seeking Alpha • Pendragony
New Tenofovir for Hep B Improves Bone and Kidney Safety (CME/CE)
MedPage Today • Liz Highleyman
Interferon-Free HCV Tx Successful in Young Kids (CME/CE)
MedPage Today • Liz Highleyman
NASH: The next untapped pharma market gives investors many options
Reuters
Pursuing Larger Rivals, NGM Bio Tries To Make Mark On Fatty Livers
Xconomy • Alex Lash
ContraVir: Disappoints Shareholders But There Is Still Hope
Seeking Alpha • Hudson River Capital Research
Gilead: Can Psoriatic Arthritis Lift This Sinking Ship?
Seeking Alpha • Abba's Aces
Gilead Sciences Near 3-Year Low. Time To Buy?
Seeking Alpha • Giovanni Dimauro
Other Hepatitis Viruses Take The Spotlight Along With Nash
Seeking Alpha • E.P. Vantage
Beaten-Down Bitoech: Gilead And Bristol-Myers Squibb
Seeking Alpha • Timothy Gornall
 
Recommended for You
Gilead Sciences, Health Finance
Gilead Sciences: A Future Dividend Gold Mine At A Bargain Price
Seeking AlphaPendragony
Summary The HCV drugs have provided a big boost to sales for GILD but that advantage is fading. The rest of GILD's drugs are doing nicely, only the oversized HCV sales make it look like GILD is struggling. While not a CCC...
Share
Gilead Sciences, Health Care Industry
New Tenofovir for Hep B Improves Bone and Kidney Safety (CME/CE)
MedPage TodayLiz Highleyman
AMSTERDAM -- Hepatitis B patients who switched to a new formulation of tenofovir showed improvements in bone and kidney safety in a pair of long-running studies, researchers reported here. Tenofovir alafenamide (TAF, sold as Vemlidy) was as effective as the older tenofovir...
Share
Gilead Sciences, GlaxoSmithKline plc
Interferon-Free HCV Tx Successful in Young Kids (CME/CE)
MedPage TodayLiz Highleyman
AMSTERDAM -- Treatment with a half-strength tablet of sofosbuvir/ledipasvir (Harvoni) for 12 weeks cured 99% of children, ages 6 to 11 years, with chronic hepatitis C, researchers reported here. All but one child treated with sofosbuvir/ledipasvir (200 mg/45 mg) for 12 weeks...
Share
Cancer, Gilead Sciences
NASH: The next untapped pharma market gives investors many options
Reuters
(Reuters) - Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.
Share
Cancer, Gilead Sciences
Pursuing Larger Rivals, NGM Bio Tries To Make Mark On Fatty Livers
XconomyAlex Lash
San Francisco — About 7,000 liver transplants occur in the U.S. each year. A condition that few people can pronounce, and no one has a treatment for, has become a main reason for those transplants. That’s why several rich, powerful drug companies...
Share
Gilead Sciences, Health Finance
ContraVir: Disappoints Shareholders But There Is Still Hope
Seeking AlphaHudson River Capital Research
Summary New 150mg and 200mg data was expected during EASL; however, ContraVir did not release this data. In all doses which have been tested so far, there were lower levels systemically of tenofovir in the blood compared to Gilead’s Viread. Two more...
Share
Gilead Sciences, Health Finance
Gilead: Can Psoriatic Arthritis Lift This Sinking Ship?
Seeking AlphaAbba's Aces
Summary Gilead and Galapagos recently announced a Phase 2 study for psoriatic arthritis. Because Galapagos initiated the Phase 2 trial for psoriatic arthritis they are due to receive a $10M milestone payment from Gilead. According to a recent study it was determined...
Share
Gilead Sciences, Health Finance
Gilead Sciences Near 3-Year Low. Time To Buy?
Seeking AlphaGiovanni Dimauro
Summary Declining earnings continues to plague the stock price. Stock nearing capitulation price of February. Technicals will likely take stock down to $60 level. President Trump's stance on health care and tough talk on bringing down the price of drugs is continuing...
Share
Gilead Sciences, Health Care Industry
Other Hepatitis Viruses Take The Spotlight Along With Nash
Seeking AlphaE.P. Vantage
Hepatitis C may have had its moment in the sun, and now biopharma has turned to other liver diseases. The meeting of the European Association for the Study of the Liver (EASL) beginning on April 19 in Amsterdam will see data in...
Share
Biotechnology, Gilead Sciences
Beaten-Down Bitoech: Gilead And Bristol-Myers Squibb
Seeking AlphaTimothy Gornall
Summary Both companies have been on substantial downtrends. Gilead appears to either be a value trap or a strong buy. Bristol-Myers Squibb is more of a rebound story. To an investor with a strong risk appetite, there may be opportunity here. Thesis...
Share